{
  "id": 345,
  "text": "This trial did not include any endpoints for recurrence or survival in these patients.LoE $^ { 2 + + }$ As part of a systematic review371 including 22 articles20,21,141,145,182,192,196,199,203,218,372-395 and evaluating the preoperative imaging and surgical staging of PALNs in locally advanced cervical cancer (FIGO stages IB2-IVA), the proportions of PALNs that were positive on histological analysis when findings on imaging were abnormal were $2 0 \\%$ to $6 6 \\%$ for CT scan, $0 \\%$ to $2 7 \\%$ for MRI, $8 6 \\%$ to $1 0 0 \\%$ for PET, and $5 0 \\%$ to $7 5 \\%$ for PET-CT.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: This trial did not include any endpoints for recurrence or survival in these patients.LoE $^ { 2 + + }$ As part of a systematic review371 including 22 articles20,21,141,145,182,192,196,199,203,218,372-395 and evaluating the preoperative imaging and surgical staging of PALNs in locally advanced cervical cancer (FIGO stages IB2-IVA), the proportions of PALNs that were positive on histological analys\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "这项研究并未包含关于局部晚期宫颈癌（FIGO阶段IB2-IVA）患者的复发或生存终点的分析。该研究主要关注于通过术前影像和手术分期评估盆腔淋巴结的情况，其中在影像检查异常时，通过病理学分析确定的阳性比例为：CT扫描为20%到66%，MRI为0%到27%，PET为86%到100%，PET-CT为50%到75%。",
  "query": "这项研究是否在分析宫颈癌患者的PALN有关的术前影像和手术分期中，考察了局部晚期宫颈癌（FIGO阶段IB2-IVA）患者的复发或生存终点？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 这项研究是否在分析宫颈癌患者的PALN有关的术前影像和手术分期中，考察了局部晚期宫颈癌（FIGO阶段IB2-IVA）患者的复发或生存终点？\n\n<reference text>: This trial did not include any endpoints for recurrence or survival in these patients.LoE $^ { 2 + + }$ As part of a systematic review371 including 22 articles20,21,141,145,182,192,196,199,203,218,372-395 and evaluating the preoperative imaging and surgical staging of PALNs in locally advanced cervical cancer (FIGO stages IB2-IVA), the proportions of PALNs that were positive on histological analysis when findings on imaging were abnormal were $2 0 \\%$ to $6 6 \\%$ for CT scan, $0 \\%$ to $2 7 \\%$ for MRI, $8 6 \\%$ to $1 0 0 \\%$ for PET, and $5 0 \\%$ to $7 5 \\%$ for PET-CT.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "这项研究并未包含关于局部晚期宫颈癌（FIGO阶段IB2-IVA）患者的复发或生存终点的分析。该研究主要关注于通过术前影像和手术分期评估盆腔淋巴结的情况，其中在影像检查异常时，通过病理学分析确定的阳性比例为：CT扫描为20%到66%，MRI为0%到27%，PET为86%到100%，PET-CT为50%到75%。"
}